Similar articles

• Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial.

  Tavares CAM, Azevedo LCP, Rea-Neto Á, Campos NS, Amendola CP, Kozesinski-Nakatani AC, David-João PG, Lobo SM, Filiponi TC, Almeida GMB, Bergo RR, Guimarães-Júnior MRR, Figueiredo RC, Castro JR, Schuler CJ, Westphal GA, Carioca ACR, Monfradini F, Nieri J, Neves FMO, Paulo JA, Albuquerque CSN, Silva MCR, Kosiborod MN, Pereira AJ, Damiani LP, Corrêa TD, Serpa-Neto A, Berwanger O, Zampieri FG; DEFENDER Investigators. Tavares CAM, et al. JAMA. 2024 Aug 6;332(5):401-411. doi: 10.1001/jama.2024.10510. JAMA. 2024. PMID: 38873723 Free PMC article. Clinical Trial.
• Empagliflozin and Major Renal Outcomes in Heart Failure.

  Packer M, Butler J, Zannad F, Pocock SJ, Filippatos G, Ferreira JP, Brueckmann M, Jamal W, Zeller C, Wanner C, Anker SD; EMPEROR Study Group. Packer M, et al. N Engl J Med. 2021 Oct 14;385(16):1531-1533. doi: 10.1056/NEJMc2112411. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449179 Clinical Trial. No abstract available.
• Dapagliflozin-induced sweet syndrome.

  Mattis DM, Limova M, Mully T. Mattis DM, et al. Cutis. 2019 Aug;104(2):E22-E24. Cutis. 2019. PMID: 31603973 No abstract available.
• Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.

  Hernandez-Quiles C, Ramirez-Duque N, Acosta-Delgado D. Hernandez-Quiles C, et al. Curr Diabetes Rev. 2019;15(4):259-262. doi: 10.2174/1573399814666180726114044. Curr Diabetes Rev. 2019. PMID: 30047331 Review.
• Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.

  Powell J, Miller SA, Taylor JR. Powell J, et al. South Med J. 2015 Feb;108(2):82-90. doi: 10.14423/SMJ.0000000000000233. South Med J. 2015. PMID: 25688892 Review.